Latest filings (excl ownership)
CT ORDER
Confidential treatment order
20 Mar 19
CT ORDER
Confidential treatment order
23 May 17
8-K
Regulation FD Disclosure
30 May 14
8-K
Bankruptcy or Receivership
20 May 14
8-K
Regulation FD Disclosure
17 Apr 14
8-K
Regulation FD Disclosure
21 Mar 14
8-K
Regulation FD Disclosure
18 Mar 14
8-K
Regulation FD Disclosure
21 Feb 14
8-K
Regulation FD Disclosure
11 Feb 14
8-K
Regulation FD Disclosure
22 Jan 14
8-K
Termination of a Material Definitive Agreement
10 Jan 14
8-K
Regulation FD Disclosure
7 Jan 14
8-K
Regulation FD Disclosure
31 Dec 13
8-K
Regulation FD Disclosure
20 Dec 13
8-K
Entry into a Material Definitive Agreement
16 Dec 13
8-K
Regulation FD Disclosure
5 Dec 13
25-NSE
Exchange delisting
27 Nov 13
25-NSE
Exchange delisting
27 Nov 13
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
21 Nov 13
10-Q
2013 Q3
Quarterly report
14 Nov 13
8-K
Regulation FD Disclosure
6 Nov 13
8-K
Regulation FD Disclosure
30 Oct 13
8-K
Entry into a Material Definitive Agreement
15 Oct 13
8-K
Departure of Directors or Certain Officers
15 Oct 13
10-Q
2013 Q2
Quarterly report
14 Aug 13
8-K
Savient Pharmaceuticals Reports Second Quarter 2013 Financial Results
14 Aug 13
8-K
Departure of Directors or Certain Officers
25 Jul 13
8-K
Savient Pharmaceuticals Announces Formation of Office of the President
20 Jun 13
8-K
Submission of Matters to a Vote of Security Holders
14 Jun 13
8-K
Regulation FD Disclosure
13 Jun 13
DEFA14A
Additional proxy soliciting materials
4 Jun 13
10-Q
2013 Q1
Quarterly report
15 May 13
8-K
Savient Pharmaceuticals Reports First Quarter 2013 Financial Results
15 May 13
DEF 14A
Definitive proxy
30 Apr 13
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
11 Apr 13
10-K
2012 FY
Annual report
1 Apr 13
EFFECT
Notice of effectiveness
1 Apr 13
POS AM
Prospectus update (post-effective amendment)
1 Apr 13
8-K
Savient Pharmaceuticals Reports Fourth Quarter and Year-End 2012 Financial Results
21 Mar 13
8-K
Savient Pharmaceuticals Announces the Election of Genzyme CEO Dr. David Meeker to Its Board of Directors
8 Jan 13